6 Stocks That Fell Off Hard in 2025

Some stocks that looked coagulated successful 2024 didn’t marque it done 2025 unscathed. Between tariffs, slower maturation and changing user habits, a fewer large names took superior hits this year.

Here are six companies that started 2025 successful decent signifier but ended it a batch little — and what a $10,000 concern successful each would look similar today.

A twelvemonth ago, star stocks were doing precise well. Enphase Energy, 1 of the apical star hardware makers, traded astir $95 successful mid-October 2024. But by October 2025, shares had crashed to astir $37.

If you’d enactment $10,000 into Enphase a twelvemonth ago, you would’ve bought astir 105 shares. Today, that concern would beryllium worthy conscionable nether $4,000, a nonaccomplishment of astir 60%.

Solar maturation slowed sharply successful 2025 arsenic higher involvement rates wounded location installations and oversupply built up successful planetary markets. Analysts had already warned successful precocious 2024 that Enphase’s maturation was cooling, and investors that kept holding are down atrocious close now.

Read More: Self-Made Millionaires Suggest 5 Stocks You Should Never Sell

Try This: 6 Safe Accounts Proven To Grow Your Money Up To 13x Faster

Nike has agelong been 1 of those “set it and hide it” stocks. But 2025 has not been their year. In October 2024, Nike traded adjacent $80 a share, but by October 2025, it had slipped to astir $69.

That means a $10,000 concern would person dropped to astir $8,600, a nonaccomplishment of astir 14%.

This wasn’t astir 1 large mistake. It was the effect of respective factors happening astatine once; Softer planetary spending, weaker China income and rising tariff concerns that spooked investors. Nike is inactive profitable, but the marketplace is being cautious with thing that could beryllium impacted by uncertain tariffs.

Biotech stocks tin soar oregon descend fast, and Sarepta is the cleanable illustration of the latter. Its shares were astir $120 successful precocious 2024, fueled by optimism implicit its cistron therapy pipeline. But by October 2025, the banal was hovering adjacent $22. Ouch!

A $10,000 concern from a twelvemonth agone would present beryllium worthy little than $1,900, a staggering an 82% loss.

Clinical proceedings results disappointed investors, and regulators raised caller concerns astir information and efficacy. Once assurance successful a biotech communicative cracks, the autumn is brutal and quick.

Peloton was the pandemic darling that couldn’t enactment connected the bike. The company’s banal crashed hard backmost successful 2021, but stabilized precocious and sat adjacent $10 a stock successful precocious 2024. But by October 2025, it was down to astir $7.60.

If you’d enactment $10,000 successful past October, your concern would beryllium worthy astir $7,600 contiguous — a 24% loss.